Clinical trials: Post-menopausal Vasomotor Symptoms
Severe Vasomotor Symptom Associated With Menopause
Post Marketing Surveillance To Observe Safety And Efficacy Of Duavive
To evaluate safety and efficacy of CE/BZA in real practice in Korea
- Trial name
- NCT02792504
- Where
- 20 sites in South Korea
- Volunteers
- 669 people
- Sponsor
- Pfizer
Major Depressive Disorder, Vasomotor Symptoms
Desvenlafaxine Succinate (Pristiq): Postmarketing Surveillance Study Among Filipino Patients
This is a non-interventional study to review safety data on administration of desvenlafaxine succinate among Filipino patients with MDD and VMS per usual clinical practice within the first three years post commercial distribution.
- Trial name
- NCT01353963
- Testing
- desvenlafaxine succinate
- Where
- 3 sites in Philippines
- Volunteers
- 13 people
- Sponsor
- Pfizer
Post-menopausal Vasomotor Symptoms
Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms
This is a multi-center, double-blind, randomized, placebo-controlled multiple ascending dose study in post-menopausal women with vasomotor symptoms. Single ascending doses of NT-814 will be investigated in 4 cohorts.
- Trial name
- RELENT-1 (NCT02865538)
- Testing
- BAY3427080
- Where
- 3 sites in United States
- Volunteers
- 76 people
- Sponsor
- Bayer
Post-menopausal Vasomotor Symptoms
Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause
In this clinical research study, subjects will be given the study drug, ACER-801 (osanetant) or placebo (looks like the study drug but contains no active ingredients).
- Trial name
- NCT05325775
- Testing
- ACER-801 50 mg BID, ACER-801 100 mg BID, ACER-801 200 mg BID
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Acer Therapeutics Inc.
Menopause, Hot Flashes
A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms
The purpose of this study is to determine the effectiveness of BAY3427080 (NT-814), taken once a day, in the treatment of troublesome post-menopausal symptoms.
- Conditions
- Menopause, Hot Flashes, Night Waking
- Trial name
- SWITCH-1 (NCT03596762)
- Testing
- Elinzanetant (BAY3427080)
- Where
- 25 sites in United States, Canada and 1 more
- Volunteers
- 199 people
- Sponsor
- Bayer